Background: Electronic cigarettes (e-cigarettes) are battery-powered devices that deliver aerosolized nicotine. With easy access and over-the-counter availability, many patients consider using electronic cigarettes for smoking cessation. Few studies have looked at long-term safety/efficacy and physician knowledge/attitudes toward e-cigarettes. Physicians have insufficient guidelines for advising their patients about e-cigarettes. Objective: 1) To identify knowledge and attitude of health care practitioners toward electronic cigarettes. 2) To identify the effect of level of training, experience and speciality on knowledge and practice of electronic cigarettes. 3) To identify factors influencing electronic cigarettes advise/prescribing practice. Methods: An anonymous online questionnaire was sent to residents, fellows, and faculty in pre-selected specialties at Saint Louis University (SLU) Hospital. Results: We received 115 responses. Nine percent reported being 'very familiar' with e-cigarettes, while 25% reported no familiarity; 18% of physicians would advise e-cigarettes as nicotine-replacement therapy if asked by patients; 91% were aware of the nicotine content of e-cigarettes, but only 20% and 39%, respectively, were aware of the presence of carcinogens and polyethylene glycol. Only 63% of respondents knew what 'vape' meant. Lack of evidence regarding long-term safety (76%), e-cigarettes as starter products for nonsmokers (50%), absence of Food and Drug Administration (FDA) regulations (51%) and marketing to youth (42%) were major concerns. Stricter regulations (54%), warning labels similar to tobacco products (53%), restricting advertising (36%), banning sales to minors (34%), and banning use in public spaces (25%) were favored as regulatory measures. More than 50% of physicians see a role for e-cigarettes as part of 'harm-reduction strategy'. Conclusions: Further research is needed to assess whether e-cigarettes could be an effective smoking-cessation tool. There is an apparent knowledge deficit among physicians and an urgent need for evidence-based guidelines to aid with advising patients enquiring about e-cigarettes.
Introduction
Electronic cigarettes (hereafter, e-cigarettes) are battery-powered devices that generate an aerosol by heating a liquid that is typically composed of a solvent (usually propylene glycol or glycerol), nicotine, and flavorings [1] . E-cigarette use is on the rise in the United States [2] [3] [4] , and many of the users report various reasons for their use, including helping them quit smoking [5] . More than half (59%) of the current smokers in the United States consider them less harmful than tobacco cigarettes [6] . In 2010, a total of 1.8% of US adults described having used e-cigarettes, a rate that surged to 13% by 2014. In 2015, 16% of US highschool students and 5.3% of middle-school students reported using them in the last 30 days. In the United States, exposure of young people to advertisements for e-cigarettes expanded by 256% between 2011 and 2013, with as many as 24 million minors exposed to these advertisements in 2013 alone [2] [3] [4] .
Notwithstanding the growing popularity, the evidence is lacking and conflicting to advocate e-cigarettes for either smoking cessation or reduction [7] . Hence there are no current evidence-based guidelines for providers to follow on the use of e-cigarettes. The US Preventive services task force and American College of Physicians recommended against the use of them as smoking cessation tool given the conflicting and limited evidence [8, 9] . However, in previously published studies the percentage of physicians who prescribed them to help quit smoking ranged from 3.7% to 46%, implying a significant variation in the clinical practice [10] [11] [12] [13] [14] [15] [16] [17] (Table 1) . Patients using e-cigs increased from 2% to 24% within the 2 years (2011-2013).
Practitioner's opinion of e-cigs being good increased significantly over the 2 years (2011-2013) from 15% to 26%.
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Healthcare professionals in public smoking-cessation clinics 79.3% agreed that e-cigs are equally effective as smoking-cessation medication. 62.6% agreed that e-cigs are safe to use.
More smokers made inquiries about e-cigs in 2014 than in 2013.
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A., et al. [21] Considering the exponential growth in awareness and use of e-cigarettes coupled with aggressive marketing by tobacco companies, physicians are increasingly engaging patients who smoke cigarettes in conversations relating to the use of e-cigarettes [10] [11] [12] [13] [14] [15] [16] [17] [18] (Table 1) . Many of the physicians lack the required knowledge and familiarity to provide informed and consistent advice for patients and their families [12, [15] [16] [17] [18] 21] (Table 1) . Hence, we sought to determine the attitudes/beliefs, concerns, and practices among physicians at Saint Louis University Hospital (SLU) regarding e-cigarettes. The results of our study could be essential in facilitating the identification of training needs and for generating clinical guidelines about e-cigarettes.
Materials and methods
This study was an SLU IRB approved cross-sectional survey consisting of a convenience sample of a cohort of physicians at SLU School of Medicine, who received an anonymous online survey between July and September 2015, consisting of multiple-choice questions regarding e-cigarettes.
An IRB approved recruitment statement was sent by the research team via email inviting residents, fellows, and attendings in pre-selected departments at SLU School of Medicine to participate in the study with a link to the survey at the bottom. Qualtrics survey software provided by the university was used to create the survey.
The study consisted of a series of 12 open and closed questions with multiple choices. Survey questions addressed participant demographics including the level of training and specialty. It also questioned participants about e-cigarettes including patient interest, physician prescription, and advocacy trends, the degree of familiarity among physicians with e-cigarettes and their contents, and concerns and measures supported by physicians to regulate e-cigarettes. This questionnaire was not validated in any prior studies (for details, see the Supplementary Appendix).
All statistical analyses were performed using IBM SPSS Statistics for Windows Version 23.0. Bivariate analyses of categorical data were conducted using Chi-square or Fisher's exact test. Multivariate logistic regression analysis was performed to explore the association between the likelihood of participants recommending e-cigarettes to patients and various characteristics of the study participants: level of training, degree of familiarity, physicians who were asked about e-cigarettes, physicians who viewed e-cigarettes as a harm-reduction tool and knew the meaning of the term 'vape'. Only statistically significant predictors are reported. P values of ≤ .05 were considered significant.
The level of training was categorized into residents, fellows, and attendings. For the descriptive statistics, specialties were reported as described in the survey.
However, during data analysis, internal medicine, geriatrics, and family medicine were defined as primary care; surgery, neurology, and psychiatry were described as 'other'; cardiology, gastroenterology, rheumatology and allergy & immunology were described as IM sub-specialties and pulmonary was reported as a separate specialty. The response of physicians when asked about e-cigarettes, concerns of the physicians about e-cigarettes, and measures advocated by doctors to regulate e-cigarettes were all tabulated and reported as percentages. Respondents were allowed to choose more than one option when answering questions. The degree of familiarity of participants was categorized as 'not at all familiar', 'somewhat familiar', and 'very familiar'. During statistical analysis, familiarity was divided into very familiar and not very familiar. Respondent's ability to correctly identify the meaning of the term 'vape' and contents of e-cigarettes was reported as the 'correct' vs. 'incorrect' answer.
Results
A total of 115 participants responded to the survey (40% response rate). Out of these 115 respondents, 45 (39%) were residents, 43 (37.4%) were attending physicians, and 27 (23.5%) were fellows. The majority of the respondents were from internal medicine (35%), internal medicine sub-specialties (27.8%), followed by pulmonary service (12%).
Only 11 (9%) respondents reported being 'very familiar', whereas 29 (25%) reported as being 'not at all familiar' with e-cigarettes ( Table 2) . Twenty-one (18.2%) participants had recommended patients to use e-cigarettes, and 58 (51%) of participants see e-cigarettes as a harm-reduction tool ( Table 2) . The majority (93%) of the interviewees reported being asked about smoking cessation by patients (9) and of these 53% of respondents were asked about ecigarettes. The results illustrated inconsistencies concerning the guidance provided to patients by practitioners when asked about e-cigarettes (Table 3) . Most frequently, practitioners replied 'I do not know much about the long-term safety and efficacy of e-cigarettes, and I would not advise you to use them' (n = 54, 48%) and 'I would recommend FDA-approved and better-studied methods' (n = 46, 41%). A minority of the physicians (n = 12, 11%) said: 'I do not know much about them and will leave the decision to you.' Only 63% of the respondents knew the meaning of the term 'vape'. Even amongst respondents who reported being either 'very familiar' or 'somewhat familiar', 28% were not able to correctly recognize the meaning of the term 'vape' ( Table 3 ). The majority (91%) of respondents were aware of the nicotine content of e-cigarettes, but only 39% were aware of the propylene glycol content, and 26% were aware of the diethylene glycol content ( Table 3) .
The majority of the respondents advocated regulations by the FDA like other tobacco products and having warning labels like other tobacco products (Table 4) . Lack of evidence regarding the long-term safety of the product, a virtual absence of regulatory controls by the FDA, and their function as attractive starter products for young non-smokers and as a gateway to smoking for adolescents were the major concerns among the respondents (Table 4) .
Respondents' degree of familiarity and the rate of patients asking about e-cigarettes did not vary by level of training or specialty. Knowledge about 'vaping' and views of e-cigarettes as a harm-reduction tool did not vary by level of training, provider specialty, or familiarity with e-cigarettes ( Table 5 ). As seen in Table 5 , providers who viewed e-cigarettes as a harm-reduction tool were more likely to advise patients. Physician's advice about e-cigarettes did not vary based on the level of training, the degree of familiarity, or provider specialty.
In multivariate analysis, providers who viewed e-cigarettes as a harm-reduction tool and were asked about e-cigarettes are more likely to prescribe e-cigarettes (OR of 4.45 and 3.8 respectively; Table 5 ).
Discussion
E-cigarettes are growing in popularity in the US, particularly among young non-smokers and adolescents. In 2015, more than 3 million middle-and highschool students were current users of e-cigarettes, making e-cigarettes the most commonly used tobacco product among youth.
In this cross-sectional survey consisting of physicians at SLU School of Medicine, we sought to determine the attitudes/beliefs, concerns, and practices among physicians regarding e-cigarettes. The results indicate that more than half see a role for e-cigarettes as part of 'harm-reduction strategy' and that an increasing number of physicians may be called on to engage in discussions with their patients about the safety and efficacy of e-cigarettes, with some providers prescribing them for smoking cessation despite lacking familiarity and having concerns about their safety. There are several important findings in our study. The first key finding is that 53% of the practitioners reported being questioned about e-cigarettes by their patients who wanted to quit smoking, irrespective of their level of training and specialty (Table 5) . Despite the frequent patient queries about e-cigarettes, our survey revealed low levels of practitioner familiarity regarding e-cigarettes. Only 9% of the respondents described being very familiar, while 25% of the interviewees stated they were not at all familiar with e-cigarettes ( Table 2 ). This degree of familiarity was irrespective of the level of training or specialty, suggesting that there is a dearth of knowledge and awareness across all training levels and specialties (Table 5 ). In our study, even amongst the respondents who reported being 'very familiar' or 'somewhat familiar', 28% were not aware of the contents of e-cigarettes or the meaning of the term 'vape', indicating a gap between stated or perceived knowledge and actual knowledge about e-cigarettes. Our findings are consistent with those from previously published studies indicating that patients seek out physicians as their source of knowledge and advice regarding e-cigarettes [10] [11] [12] [13] [14] [15] [16] [17] [18] (Table 1) , but includes several new observations, such as the observed gap between the perceived knowledge and the actual knowledge among the physicians.
A second significant finding is that 51% of respondents regard e-cigarettes as a method of harm reduction, like the methadone use or needle-exchange programs practiced in combating drug addiction. This perception among physicians was not found to be significantly associated with the level of training, the specialty of providers, or the degree of familiarity with e-cigarettes ( Table 5 ). The harm-minimization concept for tobacco must include the following three aspects: supply reduction, demand reduction, and harm reduction [23, 24] . Even if they are less harmful than conventional cigarettes [1] , advocating their use explicitly for harm reduction without addressing the exponential growth in marketing and advertisements for e-cigarettes and use among US minors and adults may do more harm than good [2] [3] [4] . To the best of our knowledge, our study is the first to evaluate physicians' perception of e-cigarettes as a harm-reduction tool.
A third key finding is that despite the evidence being conflicting and limited for advocating e-cigarettes for smoking cessation or reduction [7] , in our study 18% (n = 21) of the respondents recommended e-cigarettes for stopping smoking. The level of training, the degree of familiarity, and the specialty did not affect the likelihood of recommending e-cigarettes. In the earlier studies the percentage of physicians who prescribed e-cigarettes to help quit smoking ranged from 3.7% to 46%, consistent with findings from our study [10] [11] [12] [13] [14] [15] [16] [17] (Table 1) . Physicians who were asked about e-cigarettes were 3.8 times more inclined to advise their patients as compared to those who were not asked about e-cigarettes, which is consistent with two previous studies [10, 22] . But the providers who viewed e-cigarettes as a form of harm reduction were 4.45 times more likely to recommend e-cigarettes as compared to physicians who did not see them as a harm-reduction tool. We suggest several reasons for the above findings. First, the physicians who perceive e-cigarettes as a harmreduction tool are likely to have more positive views about e-cigarettes, thereby increasing the likelihood of recommending e-cigarettes. Second, patient interaction, news stories, and advertisements rather than evidence-based guidelines serve more frequently as sources of information about e-cigarettes for physicians [17, 18] . Hence, physicians who are asked about e-cigarettes by patients may be more inclined to prescribe them.
Finally, the majority of the respondents (91%) reported that e-cigarettes contained nicotine (Table 2) . However, only 39% of the interviewees knew e-cigarettes contained propylene glycol and 14% of the respondents stated that they contained tobacco. Analyses of the available e-cigarette liquids and aerosols displayed potentially toxic elements other than the noted ingredients, including formaldehyde, diethylene glycol, ethylene glycol, and tobacco alkaloids, although these compounds are detected at considerably lower concentrations than in traditional cigarettes [25] [26] [27] [28] . Only 20-25% of the respondents in our study were aware of the presence of these compounds in e-cigarettes, and 6/115 (5.2%) respondents were aware of all the contents in e-cigarettes. Despite the above important findings, our study has some shortcomings. Our study is limited by the small sample size of a cohort of physicians at a university hospital. Generalizing our findings to a broader base of healthcare professionals would need the use of discretion. Another limitation of the study is the 40% response rate, which seems to be low, and since the findings of this study are based on participant self-report, they are subject to possible response bias. Nonetheless, they are concordant and comparable to other physician surveys (Table 5 ). Although our survey was developed by adoption of elements used in prior studies, with inputs from other clinicians, it has not been validated. Finally, as a relatively new phenomenon, literature about electronic cigarettes continues to be published. Given the cross-sectional nature of the survey, the ability to measure future changes in physicians' attitudes regarding electronic cigarettes that might occur based on evolving literature is limited.
Conclusions
In summary, our study illustrates that more than half of the surveyed physicians see a role for e-cigarettes as part of 'harm-reduction strategy' and that an increasing number of physicians may be called on to engage in discussions with their patients about the safety and efficacy of e-cigarettes, with some providers prescribing them for smoking cessation despite lacking familiarity and having concerns about their safety. These findings have significant implications for practitioner training, as well as for future research and policy. Our study highlights a critical need for increasing awareness, educational tools, and evidence-based guidelines to aid in directing patients appropriately. As more than half the respondents were asked about e-cigarettes by their patients, it is imperative to include screening and counseling about e-cigarette use in routine clinical evaluation.
In April 2015, the American College of Physicians (ACP) released a position paper recommending that the FDA extend its regulatory authority to cover electronic nicotine delivery systems (ENDS) [8] . In November 2015, the American Academy of Pediatrics (AAP) also released a position paper calling for stricter regulation of ENDS and advising pediatricians against recommending e-cigarettes as a treatment product for tobacco dependence [29] . Considering that 81% of current youth e-cigarette users cited the availability of appealing flavors as the primary reason for use, the ACP and the AAP both called for banning flavors from all ENDS. They also recommended taxing ENDS at the same rate as conventional cigarettes to decrease youth access. The AAP also called for reducing youth access to ENDS by calling for several bans, including the sale of e-cigarettes to people younger than 21 years of age, internet sales of ENDS, and advertising of ENDS in media. All these recommendations align with the concerns that we elicited among our cohort of surveyed physicians.
In 2016, the FDA [30] extended its regulatory authority to cover all tobacco products, including vaporizers, vape pens, hookah pens, e-cigarettes, e-pipes, and all other ENDS, including the manufacture, import, packaging, labeling, advertising, promotion, sale, and distribution of ENDS. During our survey, 59% of physicians had reported the lack of FDA regulation of e-cigarettes as a major concern, an issue that has now been resolved.
Currently, it's hard to reach an agreement on the safety of e-cigarettes other than to state that they may be safer than conventional cigarettes. Given the limited knowledge of the long-term consequences of e-cigarette use on public health and smoking cessation, standardized survey methods at national and international levels, as well as continued monitoring of evolving utilization patterns of e-cigarettes, and randomized controlled head-tohead trials comparing e-cigarettes with standard therapies are crucial for public health policymaking and patient advocacy. Even as this research is under way, regulations that make e-cigarettes unavailable to children and restrict marketing and advertising, as currently instituted by the FDA, are warranted, as are public health initiatives that dissuade non-smokers from smoking conventional tobacco using e-cigarettes.
